Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
5 participants
INTERVENTIONAL
2005-12-31
2006-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Group A will receive DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, 2 and 6 months of age.
DTaP-Hep B-IPV Vaccine
U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
Placebo
Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
Group B
Group B will receive the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at 2, 4 and 6 months of age.
DTaP-Hep B-IPV Vaccine
U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
Monovalent Hep B Vaccine
U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DTaP-Hep B-IPV Vaccine
U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
Monovalent Hep B Vaccine
U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
Placebo
Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mother will deliver at a Kaiser Permanente Medical Center participating in the study
* Ability of the parent(s) to understand and comply with the requirements of the protocol
* Signed informed consent by parent(s)
* Healthy newborn 0 to 5 days of age
* Gestational age greater than or equal to 37 weeks to less than or equal to 42 weeks and birth weight greater than 2500 grams
* Signed informed consent obtained
* Mother continues to be eligible by prenatal screening criteria
* Newborn will receive future well child care at a Kaiser Permanente study clinic
* After reviewing with parent(s) the study procedures and informed consent, parent wishes to continue in the study
Exclusion Criteria
* Mother positive for human immunodeficiency virus (HIV) or whose antigen status is unknown
* Mother positive for rapid plasma reagin (RPR) (syphilis) or whose antigen status is unknown
* Mother or immediate family member has impaired immunologic function
* Mother is expected to take immune suppressant medications during the last trimester of pregnancy
* Mother is expected to receive blood, blood products or immunoglobulin preparation (including hepatitis B immune globulin \[HBIG\]) during the last trimester of the pregnancy
* Mother with insulin dependent diabetes
* Mother with pre-eclampsia, eclampsia or abruptio placentae
* Pregnancy associated with known congenital defects
* Mother participating in another study with a non-Food and Drug Administration (FDA) approved drug, vaccine or device
* Parent(s)/guardian cannot be contacted by telephone
* Parent(s)/guardian will not continue well child care at a Kaiser Permanente study clinic
* Mother who is requesting that cord blood be retained for stem cell preservation
* Other maternal conditions that, in the opinion of the investigator, would interfere with the study
* Current receipt of antibiotics for suspected infection in mother or newborn (based on presence of maternal fever greater than or equal to 38.0 degrees Celsius or prolonged rupture of membranes greater than or equal to 18 hours)
* Rectal temperature greater than or equal to 38.0 degrees Celsius
* Newborn receiving resuscitation \[including intubation, mechanical ventilation or intravenous (IV) medication\] at birth
* Suspected medical, congenital, developmental or surgical disease, including immunodeficiency, neurology disorder or seizure disorder, severe congenital anomalies or multi-organ dysfunction
* Prior receipt of hepatitis B vaccine or any other vaccine
* Received or plans to receive any immunosuppressant medication
* Receipt of blood products or immunoglobulin \[including Hepatitis B Immune Globulin (HBIG)\]
* Clinically significant findings on review of medical history and physical exam determined by the investigator or sub-investigator to be sufficient for exclusion
* Mother of newborn with insulin dependent diabetes
* Mother of newborn with pre-eclampsia, eclampsia or abruptio placentae
* Mother of newborn positive for HBsAG, HIV or RPR (syphilis) or whose antigen status is unknown
* Impaired immunologic function in newborn or family member
* Any condition determined by the investigator that would interfere with the evaluation of the vaccine or be a potential health risk to the subject
* Newborn is participating in another research study or has received a non-FDA approved drug or vaccine (excluding formula preparations) prior to study entry
* Parent(s)/guardian who are unable to be contacted by telephone
5 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
HHS/NIAID/DMID
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Center For Vaccine Research
Torrance, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
03-062
Identifier Type: -
Identifier Source: org_study_id